A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

Clinical trial NCT06559176 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT06559176
Sponsor: Prime Medicine, Inc.
Status: ENROLLING_BY_INVITATION
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Granulomatous Disease Granulomatous Disease, Chronic

Start date: 2024-10-17
Primary completion: 2030-01-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.